{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-039135","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.980975+00:00","generated_at":"2026-06-17T09:16:30.158572+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Avenue Therapeutics reports FY2022 net loss of $3.6M; cash $6.7M; pipeline updates","bullets":["Net loss $3.6M ($1.63/share) vs $3.7M ($3.29/share) in 2021; R&D $2.7M, G&A $5.3M.","Cash $6.7M at Dec 31, 2022, up from $3.8M; raised $12M in Oct 2022 offering and $3.25M in Jan 2023.","In-licensed AJ201 for SBMA (Kennedy's Disease) in Phase 1b/2a; FDA granted Orphan Drug Designation.","IV Tramadol: Type C meeting with FDA in March 2023; update expected in April 2023.","Completed acquisition of Baergic Bio in Nov 2022; appointed Alexandra MacLean to board."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-039135","json":"https://secwatch.observer/filing/0001104659-23-039135.json","markdown":"https://secwatch.observer/filing/0001104659-23-039135.md","text":"https://secwatch.observer/filing/0001104659-23-039135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923039135/0001104659-23-039135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923039135/tm2310303d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T09:16:30.158572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53ebeaaf8ef4dca81c877715a33e147378001762","claim":"AVENUE THERAPEUTICS, INC. reported the full year ended December 31, 2022 results: net income Net loss attributable to common stockholders for the full year 2022 was $3.6 million, or $1.63 per share, EPS $1.63 per share.","evidence_excerpt":"Avenue Therapeutics, Inc. issued a press release to provide a corporate update and to announce its financial results for the three months and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923039135/0001104659-23-039135-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Net income","value":"Net loss attributable to common stockholders for the full year 2022 was $3.6 million, or $1.63 per share"},{"label":"EPS","value":"$1.63 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}